JY
ARQT icon

Jeff Yass’s Arcutis Biotherapeutics ARQT Stock Holding History

Jeff Yass’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.74M Buy
333,400
+188,700
+130% +$4.4M ﹤0.01% 3610
2026
Q1 		$3.41M Sell
144,700
-127,700
-47% -$3.26M ﹤0.01% 5009
2025
Q4 		$7.91M Buy
272,400
+139,200
+105% +$3.56M ﹤0.01% 3352
2025
Q3 		$2.51M Buy
133,200
+38,400
+41% +$606K ﹤0.01% 5310
2025
Q2 		$1.33M Sell
94,800
-197,300
-68% -$2.77M ﹤0.01% 6727
2025
Q1 		$4.57M Buy
292,100
+50,600
+21% +$713K ﹤0.01% 3819
2024
Q4 		$3.36M Buy
241,500
+61,500
+34% +$674K ﹤0.01% 4256
2024
Q3 		$1.67M Buy
180,000
+17,700
+11% +$175K ﹤0.01% 5656
2024
Q2 		$1.51M Sell
162,300
-250,400
-61% -$2.26M ﹤0.01% 5658
2024
Q1 		$4.09M Buy
412,700
+398,400
+2,786% +$2.97M ﹤0.01% 3976
2023
Q4 		$46.2K Buy
+14,300
New +$38.9K ﹤0.01% 11740
2023
Q3 		– Sell
-115,300
Closed -$1.1M – 11968
2023
Q2 		$1.1M Buy
115,300
+87,900
+321% +$976K ﹤0.01% 6459
2023
Q1 		$301K Sell
27,400
-145,600
-84% -$2.11M ﹤0.01% 9707
2022
Q4 		$2.56M Buy
173,000
+130,800
+310% +$2.29M ﹤0.01% 4274
2022
Q3 		$806K Buy
42,200
+15,200
+56% +$344K ﹤0.01% 7195
2022
Q2 		$575K Buy
27,000
+8,000
+42% +$164K ﹤0.01% 7907
2022
Q1 		$366K Sell
19,000
-9,800
-34% -$166K ﹤0.01% 9755
2021
Q4 		$597K Buy
28,800
+18,100
+169% +$360K ﹤0.01% 8698
2021
Q3 		$256K Sell
10,700
-77,900
-88% -$1.78M ﹤0.01% 10958
2021
Q2 		$2.42M Buy
+88,600
New +$2.5M ﹤0.01% 5487

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jeff Yass's ARQT Position: Q2 2026 in Review

Jeff Yass increased its Arcutis Biotherapeutics (ARQT) stake by 96% in Q2 2026, buying an estimated $2.51M and bringing the position to 219,815 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4334.

Jeff Yass first reported a position in ARQT in Q2 2020 and has held it in 25 quarters since. 271 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jeff Yass held 219,815 shares of Arcutis Biotherapeutics worth $5.76M as of Q2 2026.
  • Jeff Yass bought 107,636 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.51M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4334 holding.
  • Jeff Yass first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 25 quarters since.
  • 271 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.